Income statement waterfall. Green diagonal stripes add to the running result, red diagonal stripes subtract from it, and a thin axis line marks the loss-zone boundary.
- Revenue: $496.01M. Running result $496.01M. Aristada And Aristada Initio: $96.72M. LUMRYZ: $96.57M. LYBALVI: $93.98M. Manufacturing Revenue: $20.9M. Royalty: $63.38M. Vivitrol: $124.45M.
- Cost of revenue: −$98.11M. Running result $397.9M.
- Gross profit: $397.9M. Running result $397.9M.
- Research and development: −$112.92M. Running result $284.98M.
- Selling, general and administrative: −$217.63M. Running result $67.35M.
- Change in fair value of contingent consideration: −$26.41M. Running result $40.94M.
- Amortization of acquired intangible assets: −$22.59M. Running result $18.35M.
- Operating income: $18.35M. Running result $18.35M.
- Other expense: −$20.23M. Running result −$1.88M.
- Pre-tax loss: −$1.88M. Running result −$1.88M.
- Income tax benefit: $2.38M. Running result $501K.
- Net income: $501K. Running result $501K.